Surveys on public attitudes to science regularly tell us that there are swathes of the public that simply seem to not care about science, despite our best effort to engage them. But perhaps the issue is not with the public - the issue is with the question. [ + ]

Arcitecta is developing a product to improve the capture and management of data from clinical research worldwide. The work builds on the company's metadata management platform, Mediaflux, "but extends its capabilities for clinical research data capture and management", according Arcitecta Chief Technical Officer Jason Lohrey. [ + ]

Detect, destroy, remember is the mantra of the immune system as it campaigns against infectious invaders and the body's own abnormal cells. And now immunotherapy is finally offering viable treatment options for some cancers. [ + ]

Microscopy researchers at North Carolina State University have developed a technique that eliminates the distortion encountered when capturing images at the atomic scale. Their method will be reported in the March issue of Ultramicroscopy. [ + ]

Neuren (ASX:NEU) is well underway with clinical trials of drug candidate NNZ-2566 in neurological conditions including Fragile X syndrome, Rett syndrome and traumatic brain injury. [ + ]

New Queensland recruit Dr Roberta Mazzieri is passionate about understanding the complex and dangerous cellular interactions that make up a tumour microenvironment. Specifically, she wants to hijack one cell component of this environment and use its cancer-promoting powers for good, not evil. [ + ]

Starpharma (ASX:SPL) has received the approvals required to kick off the first human trial of dendrimer-enhanced chemotherapy formulation DEP-docetaxel. [ + ]

Victoria University is one of New Zealand's most respected universities. Based in the seismically active area of Wellington and subject to several significant earthquakes in recent years, the university's Infrastructure Services team was tasked with the development of a disaster recovery (DR) data centre. [ + ]

The Australian Academy of Science has announced this year's winners of its prestigious annual awards for scientific excellence. As Academy President Professor Suzanne Cory explained, "These awards celebrate both career-long contributions by some of Australia's most distinguished researchers and remarkable discoveries made by younger investigators." [ + ]

Shakespeare’s Hamlet was correct - "what a piece of work is a [hu]man! ... how infinite in faculty" - and now it seems, according to a team of researchers in Sydney, in gene expression regulation. [ + ]

Long-term follow-up data from a trial of Patrys's (ASX:PAB) IgM antibody PAT-SC1 in gastric cancer shows improved 10-year survival rates in treated patients. [ + ]

Abraxane, a chemotherapy drug licensed in Australia by STA, achieved a three-year overall survival of 4% during a combination trial in metastatic pancreatic cancer. [ + ]

Solving the structure of proteins is all in a day's work for Dr Megan Maher, who is using X-ray crystallography to further our understanding of how cells acquire and use trace metals. [ + ]

Belgium's FAMHP has become the first regulator to sign off on the modified protocol for Prima BioMed's (ASX:PRR) upcoming trial of CVac in ovarian cancer. [ + ]

Using sea urchin eggs as a model system, Professor Jens Coorssen is unveiling the mechanisms underlying the essential cellular process of vesicular release and paving the way for this pathway to be targeted in rational drug development. [ + ]